We are live on ! Find out more
BIOT

Biotech Acquisition Company Class A Ordinary Shares
BIOT

Delisted

BIOT was delisted on the 2nd of February, 2023.

Back to rankings

76 hedge funds and large institutions have $211M invested in Biotech Acquisition Company Class A Ordinary Shares in 2021 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 8

44% more capital invested

Capital invested by funds: $146M → $211M (+$64.9M)

31% more funds holding

Funds holding: 58 → 76 (+18)

10% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 10

Holders
76
Holders Change
+18
Holders Change %
+31.03%
% of All Funds
1.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
9
Reduced
10
Closed
8
Calls
$96K
Puts
–
Net Calls
+$96K
Net Calls Change
-$2K

Top Buyers

Rank Fund Capital Flow
1
AC
Aristeia Capital
Connecticut
+$11.3M
2
CM
Cohanzick Management
New York
+$7.84M
3
RA
RiverPark Advisors
New York
+$7.84M
4
Marshall Wace
Marshall Wace
United Kingdom
+$5.9M
5
WCMNY
Westchester Capital Management (New York)
New York
+$5.11M

Top Sellers

Rank Fund Capital Flow
1
SRCM
Sage Rock Capital Management
New York
-$5.59M
2
ACM
Atalaya Capital Management
New York
-$5.4M
3
MP
Mangrove Partners
Connecticut
-$2.92M
4
CC
Centiva Capital
New York
-$2.42M
5
PP
Paloma Partners
Connecticut
-$498K
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
26
Sculptor Capital
New York
$2.95M – – –
HCM
27
Hawkeye Capital Management
Florida
$2.95M +$2.94M +300,000 New
Bank of Montreal
28
Bank of Montreal
Ontario, Canada
$2.47M +$491K +50,000 +25%
Deutsche Bank
29
Deutsche Bank
Germany
$2.46M – – –
Goldman Sachs
30
Goldman Sachs
New York
$2.29M -$11.7K -1,194 -0.5%
RCM
31
Rivernorth Capital Management
Florida
$2.21M – – –
CH
32
CVI Holdings
Delaware
$2.21M +$245K +24,957 +12%
CCM
33
Context Capital Management
California
$1.91M +$1.91M +194,400 New
Bank of America
34
Bank of America
North Carolina
$1.64M – – –
WAM
35
Wolverine Asset Management
Illinois
$1.63M -$108K -10,954 -6%
Alyeska Investment Group
36
Alyeska Investment Group
Illinois
$1.48M – – –
PMAM
37
Picton Mahoney Asset Management
Ontario, Canada
$1.48M – – –
AC
38
Antara Capital
New York
$1.48M +$1.47M +150,000 New
TCM
39
Tenor Capital Management
New York
$1.42M – – –
Jane Street
40
Jane Street
New York
$1.32M – – –
Millennium Management
41
Millennium Management
New York
$1.31M – – –
WA
42
Whitebox Advisors
Minnesota
$1.23M – – –
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$1.21M +$1.21M +123,284 New
BCM
44
Basso Capital Management
Connecticut
$1.18M -$276K -28,138 -19%
Capstone Investment Advisors
45
Capstone Investment Advisors
New York
$1.17M – – –
GCL
46
Glazer Capital LLC
New York
$1.09M +$1.09M +110,599 New
SCM
47
Shaolin Capital Management
Florida
$1.05M +$1.05M +106,888 New
AA
48
AQR Arbitrage
Connecticut
$995K – – –
LP
49
LMR Partners
United Kingdom
$984K – – –
FTCM
50
First Trust Capital Management
Illinois
$984K +$98.2K +10,001 +11%
1
2
3 4

BIOT Hedge Fund Activity: Q4 2021 in Review

76 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Class A Ordinary Shares (BIOT) for Q4 2021, worth a combined $211M — up 44% from $146M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BIOT positions and 8 closed out — a net gain of 18 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Aristeia Capital, opening a new position worth an estimated $11.3M. The largest seller was Sage Rock Capital Management, exiting entirely with an estimated $5.59M sold.

  • 76 institutional investors held Biotech Acquisition Company Class A Ordinary Shares (BIOT) as of Q4 2021, up from 58 in Q3 2021.
  • Funds reported $211M of Biotech Acquisition Company Class A Ordinary Shares stock for Q4 2021, up 44% quarter-over-quarter.
  • 26 funds opened new Biotech Acquisition Company Class A Ordinary Shares positions in Q4 2021 and 8 closed out, a net change of +18 holders.
  • The largest Biotech Acquisition Company Class A Ordinary Shares buyer in Q4 2021 was Aristeia Capital, an estimated $11.3M added.
  • The largest Biotech Acquisition Company Class A Ordinary Shares seller in Q4 2021 was Sage Rock Capital Management, an estimated $5.59M sold.

Based on aggregated 13F filings for Q4 2021.